-
公开(公告)号：US20230013293A1
公开(公告)日：2023-01-19
申请号：US17685056
申请日：2022-03-02
Applicant: FIVE PRIME THERAPEUTICS, INC.
Inventor： Charles Kaplan , Derrick Houser , Luis Borges , Gloria Brattich , David Bellovin , Felicia Kemp , Majid Ghoddusi , Nels P. Nielson , Kathy Miller , Maike Schmidt
IPC: C07K16/28 , A61P35/00 , G01N33/574
Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human B7-H4 (and optionally cynomolgus monkey, mouse, and/or rat B7-H4) and compositions comprising such antibodies or antigen-binding fragments thereof. In a specific aspect, the antibodies or antigen-binding fragments thereof that specifically bind to human B7-H4 increase T cell proliferation, increase interferon-gamma production, and/or deplete B7-H4 expressing cells via ADCC activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody or antigen-binding fragment thereof that specifically binds to human B7-H4.
-
公开(公告)号：US20190085080A1
公开(公告)日：2019-03-21
申请号：US16111064
申请日：2018-08-23
Applicant: Five Prime Therapeutics, Inc.
Inventor： Charles Kaplan , Derrick Houser , Luis Borges , Gloria Brattich , David Bellovin , Felicia Kemp , Majid Ghoddusi , Nels P. Nielson , Kathy Miller , Maike Schmidt
IPC: C07K16/28 , A61P35/00 , G01N33/574
Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human B7-H4 (and optionally cynomolgus monkey, mouse, and/or rat B7-H4) and compositions comprising such antibodies or antigen-binding fragments thereof. In a specific aspect, the antibodies or antigen-binding fragments thereof that specifically bind to human B7-H4 increase T cell proliferation, increase interferon-gamma production, and/or deplete B7-H4 expressing cells via ADCC activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody or antigen-binding fragment thereof that specifically binds to human B7-H4.
-
公开(公告)号：US20160152715A1
公开(公告)日：2016-06-02
申请号：US14925534
申请日：2015-10-28
Inventor： Brian Wong , Julie Hambleton , Robert Sikorski , Emma Masteller , Kevin Hestir , David Bellovin , Katherine E. Lewis
CPC classification number: C07K16/2866 , A61K2039/505 , A61K2039/507 , A61K2039/54 , A61K2039/545 , C07K16/2803 , C07K16/2818 , C07K16/3046 , C07K16/3069 , C07K2317/24 , C07K2317/33 , C07K2317/565 , C07K2317/76 , C07K2317/90 , C07K2317/92
Abstract: Methods of treating cancer with antibodies that bind colony stimulating factor 1 receptor (CSF1R) in combination with PD-1/PD-L1 inhibitors are provided.
Abstract translation: 提供了与PD-1 / PD-L1抑制剂结合使用结合集落刺激因子1受体（CSF1R）的抗体治疗癌症的方法。
-
公开(公告)号：US20160106809A1
公开(公告)日：2016-04-21
申请号：US14890047
申请日：2014-05-22
Inventor： David Bellovin , Kevin Baker , Thomas Brennan , Arundathy Nirmalini Pandite , Bijoyesh Mookerjee , Maurice P. DeYoung , Rakesh Kumar
IPC: A61K38/17 , A61K33/24 , A61K31/337 , G01N33/574 , A61K31/519 , C07K14/71 , C12Q1/68 , A61K45/06 , A61K31/555
CPC classification number: A61K38/179 , A61K31/337 , A61K31/519 , A61K31/555 , A61K33/24 , A61K45/06 , C07K14/71 , C07K2319/30 , C12Q1/6886 , C12Q2600/106 , C12Q2600/158 , G01N33/574 , G01N33/57496 , G01N2333/49 , G01N2333/50 , G01N2333/503 , G01N2333/515 , G01N2800/52
Abstract: Methods of treating cancers comprising administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule are provided. Methods of treating cancers comprising administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule and at least one anti-angiogenic agent are provided.
Abstract translation: 提供了包括施用成纤维细胞生长因子受体1（FGFR1）细胞外结构域（ECD）和/或FGFR1 ECD融合分子的癌症治疗方法。 提供了包括施用成纤维细胞生长因子受体1（FGFR1）细胞外结构域（ECD）和/或FGFR1 ECD融合分子和至少一种抗血管生成剂的治疗癌症的方法。
-
公开(公告)号：US20230212299A1
公开(公告)日：2023-07-06
申请号：US18069511
申请日：2022-12-21
Inventor： Brian Wong , Julie Hambleton , Robert Sikorski , Emma Masteller , Kevin Hestir , David Bellovin , Katherine E. Lewis
CPC classification number: C07K16/2863 , C07K16/2896 , A61P35/00 , C07K2317/565
Abstract: Methods of treating cancer with antibodies that bind colony stimulating factor 1 receptor (CSF1R) in combination with PD-1/PD-L1 inhibitors are provided.
-
Patent Agency Ranking
公开(公告)号：US20200237927A1
公开(公告)日：2020-07-30
申请号：US16786158
申请日：2020-02-10
Applicant: Five Prime Therapeutics, Inc.
Inventor： Emma Masteller , Thomas Brennan , David Bellovin , Kevin Baker , Brian Wong
Abstract: Methods of treating cancer with antibodies that bind colony stimulating factor 1 receptor (CSF1R) in combination with one or more immune stimulating agents are provided.
-
公开(公告)号：US20180094067A1
公开(公告)日：2018-04-05
申请号：US15680664
申请日：2017-08-18
Inventor： Brian Wong , Julie Hambleton , Robert Sikorski , Emma Masteller , Kevin Hestir , David Bellovin , Katherine E. Lewis
CPC classification number: C07K16/2866 , A61K2039/505 , A61K2039/507 , A61K2039/54 , A61K2039/545 , C07K16/2803 , C07K16/2818 , C07K16/3046 , C07K16/3069 , C07K2317/24 , C07K2317/33 , C07K2317/565 , C07K2317/76 , C07K2317/90 , C07K2317/92
Abstract: Methods of treating cancer with antibodies that bind colony stimulating factor 1 receptor (CSF1R) in combination with PD-1/PD-L1 inhibitors are provided.
-
公开(公告)号：US20180085472A1
公开(公告)日：2018-03-29
申请号：US15564866
申请日：2016-04-12
Applicant: Five Prime Therapeutics, Inc.
Inventor： Emma Masteller , Thomas Brennan , David Bellovin , Kevin Baker , Brian Wong
CPC classification number: A61K47/6879 , A61K47/6851 , A61K51/1084 , A61K2039/507 , A61P35/00 , C07K16/2866 , C07K16/2878
Abstract: Methods of treating cancer with antibodies that bind colony stimulating factor 1 receptor (CSF1R) in combination with one or more immune stimulating agents are provided.
-
公开(公告)号：US20170145071A1
公开(公告)日：2017-05-25
申请号：US15340238
申请日：2016-11-01
Applicant: Five Prime Therapeutics, Inc.
Inventor： Thomas Brennan , David Bellovin , David Busha , Barbara Sennino
IPC: C07K14/705 , A61K38/17 , A61K39/395 , C07K16/28 , C07K16/00 , A61K45/06
CPC classification number: C07K14/70532 , A61K38/00 , A61K38/1774 , A61K39/39558 , A61K45/06 , C07K16/00 , C07K16/2803 , C07K2317/41 , C07K2319/03 , C07K2319/30
Abstract: This application relates to CD80 (B7-1) extracellular domain (ECD) polypeptides and CD80-ECD fusion molecules and their use in treatment of cancer, both alone and in combination with other therapeutic agents, such as immune stimulating agents such as PD-1/PD-L1 inhibitors.
-
公开(公告)号：US11814431B2
公开(公告)日：2023-11-14
申请号：US16814627
申请日：2020-03-10
Applicant: Five Prime Therapeutics, Inc.
Inventor： Charles Kaplan , Derrick Houser , Luis Borges , Gloria Brattich , David Bellovin , Felicia Kemp , Majid Ghoddusi , Nels P. Nielson , Kathy Miller , Maike Schmidt
IPC: C07K16/28 , A61K39/395 , G01N33/53 , A61P35/00 , G01N33/574 , A61K39/00
CPC classification number: C07K16/2827 , A61P35/00 , C07K16/2818 , G01N33/57492 , A61K2039/505 , A61K2039/507 , C07K2317/21 , C07K2317/24 , C07K2317/40 , C07K2317/41 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/732 , C07K2317/74 , C07K2317/75 , C07K2317/76 , C07K2317/92
Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human B7-H4 (and optionally cynomolgus monkey, mouse, and/or rat B7-H4) and compositions comprising such antibodies or antigen-binding fragments thereof. In a specific aspect, the antibodies or antigen-binding fragments thereof that specifically bind to human B7-H4 increase T cell proliferation, increase interferon-gamma production, and/or deplete B7-H4 expressing cells via ADCC activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody or antigen-binding fragment thereof that specifically binds to human B7-H4.
-
-
-
-
-
-
-
-
-
Search Results
26
records
(took 0.022 seconds)
